| |
| |
|
| Insider
Information: |
Levin Mark J |
| Relationship: |
10% Owner |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
13 |
|
| Direct
Shares |
42,729,845 |
|
|
Indirect Shares
|
23,401,954 |
|
|
| Direct
Value |
$190,595,846 |
|
|
|
Indirect Value
|
$636,697,936 |
|
|
| Total
Shares |
66,131,799 |
|
|
| Total
Value |
$827,293,782 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
8
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
8
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-8.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -215.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Millennium Pharmaceuticals Inc |
MLNM |
Director |
2008-05-09 |
0 |
2008-04-18 |
405,895 |
Premium* |
|
|
Foundation Medicine, Inc. |
FMI |
Director, 10% Owner |
2014-05-12 |
17,462 |
2014-05-12 |
0 |
Premium* |
|
|
Carisma Therapeutics Inc |
CARM |
Director, 10% Owner |
2014-02-11 |
4,841,591 |
2014-02-05 |
330,708 |
Premium* |
|
|
Larimar Therapeutics Inc |
LRMR |
10% Owner |
2014-06-24 |
5,602,045 |
2014-06-24 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
10% Owner |
2014-07-23 |
11,681,008 |
|
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
Director, 10% Owner |
2018-09-19 |
33,029 |
2018-09-19 |
6,394,845 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
10% Owner |
2017-03-16 |
111,244 |
2017-03-16 |
3,453,753 |
Premium* |
|
|
Neon Therapeutics, Inc. |
NTGN |
10% Owner |
2018-06-29 |
9,741,636 |
2018-06-29 |
0 |
Premium* |
|
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2018-08-30 |
3,278,752 |
2018-08-30 |
0 |
Premium* |
|
|
Fulcrum Therapeutics, Inc. |
FULC |
Director, 10% Owner |
2021-11-10 |
75,800 |
2021-11-10 |
3,970,625 |
Premium* |
|
|
Jounce Therapeutics Inc |
JNCE |
10% Owner |
2021-09-15 |
3,549,881 |
2021-09-15 |
3,048,780 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2021-06-04 |
374,848 |
2021-06-04 |
5,536,956 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-06 |
3,422,549 |
2021-05-06 |
260,392 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
101 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| JNCE |
Jounce Therapeutics Inc |
10% Owner |
– – • |
2021-03-11 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,250,000) |
6,500,349 |
0 |
% |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2021-05-06 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,085,784) |
3,422,549 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
10% Owner |
– – • |
2021-06-10 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,500,000) |
4,447,829 |
0 |
% |
|
| JNCE |
Jounce Therapeutics Inc |
10% Owner |
– – • |
2021-09-15 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,750,000) |
2,697,829 |
0 |
% |
|
| FULC |
Fulcrum Therapeutics, Inc... |
Director |
– • • |
2021-09-22 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,000,000) |
4,962,202 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
Director |
– • • |
2021-11-10 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,000,000) |
3,962,202 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-02-08 |
4 |
AS |
$10.76 |
$3,228 |
D/D |
(300) |
3,041,024 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-06-27 |
4 |
AS |
$10.21 |
$5,208 |
D/D |
(500) |
2,874,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-11-14 |
4 |
AS |
$13.79 |
$5,599 |
D/D |
(400) |
2,744,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-11-21 |
4 |
AS |
$14.11 |
$5,660 |
D/D |
(400) |
2,734,224 |
0 |
- |
|
| CARM |
Carisma Therapeutics Inc |
Director |
– • • |
2014-02-11 |
4 |
A |
$0.00 |
$8,069 |
D/D |
3,959,401 |
4,290,109 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-11-28 |
4 |
AS |
$14.97 |
$12,152 |
D/D |
(800) |
2,724,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-12-12 |
4 |
AS |
$15.50 |
$13,985 |
D/D |
(900) |
2,704,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-12-19 |
4 |
AS |
$15.02 |
$16,566 |
D/D |
(1,100) |
2,694,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-12-05 |
4 |
AS |
$15.06 |
$16,770 |
D/D |
(1,100) |
2,714,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2008-01-09 |
4 |
AS |
$14.83 |
$28,611 |
D/D |
(1,900) |
2,664,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-11-07 |
4 |
AS |
$12.87 |
$37,838 |
D/D |
(2,900) |
2,754,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2008-01-02 |
4 |
AS |
$15.68 |
$42,306 |
D/D |
(2,600) |
2,674,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-11-07 |
4 |
AS |
$12.88 |
$93,636 |
D/D |
(7,100) |
2,757,124 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-08-29 |
4 |
AS |
$9.66 |
$97,566 |
D/D |
(10,000) |
2,814,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-06-27 |
4 |
AS |
$9.95 |
$97,951 |
D/D |
(9,500) |
2,874,724 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-08-22 |
4 |
AS |
$9.75 |
$98,196 |
D/D |
(10,000) |
2,824,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-09-12 |
4 |
AS |
$9.89 |
$100,041 |
D/D |
(10,000) |
2,794,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-08-01 |
4 |
AS |
$9.96 |
$100,967 |
D/D |
(10,000) |
2,854,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2007-09-05 |
4 |
AS |
$10.07 |
$101,425 |
D/D |
(10,000) |
2,804,224 |
0 |
- |
|
101 Records found
|
|
Page 2 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
